Contineum Therapeutics, Inc.

CTNM

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Baker Bros. Advisors Commodore Capital RA Capital Management

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management7.2%Feb 17, 2026

SC 13GRA Capital Management9.9%Jul 25, 2025

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 1,420,838Value: $16.2M

## Signal Note: Baker Bros. Initiates Position in Contineum Therapeutics (CTNM) **Note: The reported position value of ~$16.2B appears to be a data error — likely reflecting an uncorrected multiplier, as CTNM's entire market cap is roughly $1.2-1.5B. The actual position (~1.42M shares) is likely worth ~$16-17M based on recent share prices.** That said, Baker Bros. initiating any new position in a pre-revenue neuroscience company is a meaningful signal given their track record of deep clinical diligence and concentrated, conviction-driven portfolio construction. CTNM's lead asset, **CTNM-001 (a selective S1P1 receptor modulator)**, is in development for **neuropsychiatric and neuroinflammatory indications**, with the company advancing toward clinical data

Commodore CapitalNEW

More CTNM Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SYRE4 funds NUVL4 funds RLAY4 funds BCRX3 funds CNTA3 funds CTMX3 funds IRON3 funds EWTX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Commodore Capital initiates $9.3M position in CTNM** Pellini's entry into Contineum suggests confidence in the company's precision oncology pipeline, particularly its lead program targeting DNA repair pathways in solid tumors. Given Pellini's track record building Foundation Medicine around molecular diagnostics-driven treatment selection, this signals potential near-term clinical or partnership catalysts that could validate Contineum's biomarker-driven approach.